Outcome in Elderly Patients with Cardiogenic Shock Complicating Acute Myocardial Infarction

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Introduction:Despite advances in treatment of patients with cardiogenic shock following acute myocardial infarction (AMICS) in-hospital mortality remains around 50%. Outcome varies among patient subsets and the elderly often have a poor a priori prognosis. We sought to investigate outcome among elderly AMICS patients referred to evaluation and treatment at a tertiary university hospital.Methods:Current analysis was based on the RETROSHOCK registry comprising consecutive AMICS patients admitted to tertiary care. Patients in the registry were individually identified and validated.Results:Of 1,716 admitted patients, 496 (28.9%) patients were ≥75 years old. Older patients were less likely to be admitted directly to a tertiary centre (59.4% vs. 69.9%, P = 0.003), receive mechanical support devices (i.e., Impella® (8.9% vs. 15.0%, P = 0.003), and undergo revascularization attempt (76.8% vs. 90.2%, P < 0.001). Thirty-day survivors ≥75 years were characterized by having higher left ventricular ejection fraction (30.2% ± 12.5% vs. 26.5% ± 11.8%, P = 0.004) and lower arterial lactate (3.2[2.2-5.2] mmol/L vs. 5.5[3.3-8.2] mmol/L, P < 0.001) at admission. In a multivariable analysis of patients ≥75 years, higher age (HR 1.09, 95% CI 1.05-1.14, P < 0.001), higher heart rate (HR 1.01, 95% CI 1.001-1.014, P = 0.03), and higher lactate (HR 1.11, 95% CI 1.07-1.16, P < 0.001) at admission were associated with an increased risk of 30-day mortality.Conclusion:Among patients ≥75 years with AMICS referred for tertiary specialized treatment, 30-day mortality was 73.4%. Survivors were characterized by lower arterial lactate and heart rate at admission.

OriginalsprogEngelsk
TidsskriftShock
Vol/bind57
Udgave nummer3
Sider (fra-til)327-335
Antal sider9
ISSN1073-2322
DOI
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
Dr Jacob Eifer Møller has received research grant and speakers fee from Abiomed. Dr Hanna Ratcovich has received research grants from Murermester Lauritz Peter Christensen og hustru Kirsten Sigrid Christensens foundation and Snedkermester Sophus Jacobsen og hustru Astrid Jacobsens foundation.

Publisher Copyright:
© 2022 Lippincott Williams and Wilkins. All rights reserved.

ID: 310433486